We are live on ! Find out more
AEON.WS

AEON Biopharma Inc
AEON.WS

Delisted

AEON.WS was delisted on the 26th of April, 2024.

Back to rankings

42 hedge funds and large institutions have $572K invested in AEON Biopharma Inc in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 49 → 42 (-7)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

71% less call options, than puts

Call options by funds: $19K | Put options by funds: $66K

80% less capital invested

Capital invested by funds: $2.87M → $572K (-$2.29M)

Holders
42
Holders Change
-7
Holders Change %
-14.29%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
7
Closed
10
Calls
$19K
Puts
$66K
Net Calls
-$47K
Net Calls Change
-$399K

Top Buyers

Rank Fund Capital Flow
1
SIM
Sandia Investment Management
Massachusetts
+$7.32K
2
LOAMU
Lombard Odier Asset Management (USA)
New York
+$3.13K
3
CAC
Cowen and Company
New York
+$1.76K
4
VF
Virtu Financial
New York
+$1.35K
5
SSA
Schonfeld Strategic Advisors
New York
+$536

Top Sellers

Rank Fund Capital Flow
1
AC
Athos Capital
Hong Kong
-$302K
2
SCM
Shaolin Capital Management
Florida
-$54.8K
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$28.3K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.37K
5
CH
CVI Holdings
Delaware
-$4.33K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Segantii Capital Management
Hong Kong
$118K – – –
CF
2
Cantor Fitzgerald
New York
$53.7K – – –
PC
3
Periscope Capital
Ontario, Canada
$44.3K -$1.92K -25,500 -5%
Parallax Volatility Advisers
4
Parallax Volatility Advisers
California
$43.5K -$28.3K -377,003 -44%
AC
5
Aristeia Capital
Connecticut
$28.3K – – –
CAC
6
Cowen and Company
New York
$27.7K +$1.76K +23,400 +8%
DKCM
7
Davidson Kempner Capital Management
New York
$27.5K – – –
RCM
8
Radcliffe Capital Management
Pennsylvania
$24.6K – – –
LP
9
LMR Partners
United Kingdom
$18K – – –
TCM
10
Tenor Capital Management
New York
$15K – – –
KC
11
Kepos Capital
New York
$14K +$11.6K +153,920 New
QGA
12
Q Global Advisors
Texas
$12K – – –
BNP Paribas Financial Markets
13
BNP Paribas Financial Markets
France
$10.4K – – –
UOC
14
UBS O'Connor
Illinois
$9.26K -$267 -3,555 -3%
Hudson Bay Capital Management
15
Hudson Bay Capital Management
Connecticut
$9K – – –
SIM
16
Sandia Investment Management
Massachusetts
$8.77K +$7.32K +97,449 New
Wells Fargo
17
Wells Fargo
California
$8.52K – – –
WA
18
Whitebox Advisors
Minnesota
$8.28K – – –
Calamos Advisors
19
Calamos Advisors
Illinois
$7.5K – – –
KL
20
KIM LLC
Kansas
$7.5K – – –
CCA
21
Castle Creek Arbitrage
Colorado
$7.23K – – –
Goldman Sachs
22
Goldman Sachs
New York
$7.16K – – –
SC
23
Sculptor Capital
New York
$5.38K -$180 -2,400 -4%
LIM
24
Longfellow Investment Management
Massachusetts
$4.64K -$1K -13,333 -21%
AA
25
AQR Arbitrage
Connecticut
$4.5K – – –
1
2 3

AEON.WS Hedge Fund Activity: Q2 2023 in Review

42 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q2 2023, worth a combined $572K — down 80% from $2.87M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AEON.WS and 4 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Sandia Investment Management, opening a new position worth an estimated $7.32K. The largest seller was Athos Capital, exiting entirely with an estimated $302K sold.

  • 42 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q2 2023, down from 49 in Q1 2023.
  • Funds reported $572K of AEON Biopharma Inc stock for Q2 2023, down 80% quarter-over-quarter.
  • 4 funds opened new AEON Biopharma Inc positions in Q2 2023 and 10 closed out, a net change of -6 holders.
  • The largest AEON Biopharma Inc buyer in Q2 2023 was Sandia Investment Management, an estimated $7.32K added.
  • The largest AEON Biopharma Inc seller in Q2 2023 was Athos Capital, an estimated $302K sold.

Based on aggregated 13F filings for Q2 2023.